IE
SION

Israel Englander’s Sionna Therapeutics SION Stock Holding History

Israel Englander’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$880K Buy
+20,000
New +$800K ﹤0.01% 4400

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Israel Englander's SION Position: Q2 2026 in Review

Israel Englander increased its Sionna Therapeutics (SION) stake by 97% in Q2 2026, buying an estimated $5.44M and bringing the position to 276,733 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2090.

Israel Englander first reported a position in SION in Q1 2025 and has held it in 6 quarters since. 146 funds tracked by Wall St. Rank hold SION as of Q2 2026.

  • Israel Englander held 276,733 shares of Sionna Therapeutics worth $12.2M as of Q2 2026.
  • Israel Englander bought 136,092 Sionna Therapeutics shares in Q2 2026, an estimated $5.44M.
  • Sionna Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2090 holding.
  • Israel Englander first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 146 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.